Literature DB >> 19303813

Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England.

Bernard Rachet1, Camille Maringe, Ula Nur, Manuela Quaresma, Anjali Shah, Laura M Woods, Libby Ellis, Sarah Walters, David Forman, John Steward, Michel P Coleman.   

Abstract

BACKGROUND: The National Health Service (NHS) cancer plan for England was published in 2000, with the aim of improving the survival of patients with cancer. By contrast, a formal cancer strategy was not implemented in Wales until late 2006. National data on cancer patient survival in England and Wales up to 2007 thus offer the opportunity for a first formal assessment of the cancer plan in England, by comparing survival trends in England with those in Wales before, during, and after the implementation of the plan.
METHODS: We analysed population-based survival in 2.2 million adults diagnosed with one of 21 common cancers in England and Wales during 1996-2006 and followed up to Dec 31, 2007. We defined three calendar periods: 1996-2000 (before the cancer plan), 2001-03 (initialisation), and 2004-06 (implementation). We estimated year-on-year trends in 1-year relative survival for patients diagnosed during each period, and changes in those trends between successive periods in England and separately in Wales. Changes between successive periods in mean survival up to 5 years after diagnosis were analysed by country and by government office region of England. Life tables for single year of age, sex, calendar year, deprivation category, and government office region were used to control for background mortality in all analyses.
FINDINGS: 1-year survival in England and Wales improved for most cancers in men and women diagnosed during 1996-2006 and followed until 2007, although not all trends were significant. Annual trends were generally higher in Wales than in England during 1996-2000 and 2001-03, but higher in England than in Wales during 2004-06. 1-year survival for patients diagnosed in 2006 was over 60% for 12 of 17 cancers in men and 13 of 18 cancers in women. Differences in 3-year survival trends between England and Wales were less marked than the differences in 1-year survival. North-South differences in survival trends for the four most common cancers were not striking, but the North West region and Wales showed the smallest improvements during 2001-03 and 2004-06.
INTERPRETATION: The findings indicate slightly faster improvement in 1-year survival in England than in Wales during 2004-06, whereas the opposite was true during 2001-03. This reversal of survival trends in 2001-03 and 2004-06 between England and Wales is much less obvious for 3-year survival. These different patterns of survival suggest some beneficial effect of the NHS cancer plan for England, although the data do not so far provide a definitive assessment of the effectiveness of the plan.

Entities:  

Mesh:

Year:  2009        PMID: 19303813     DOI: 10.1016/S1470-2045(09)70028-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  74 in total

1.  Measuring NHS performance 1990-2009 using amenable mortality: interpret with care.

Authors:  Monica Desai; Ellen Nolte; Marina Karanikolos; Bernadette Khoshaba; Martin McKee
Journal:  J R Soc Med       Date:  2011-09       Impact factor: 5.344

2.  Expensive cancer drugs: a comparison between the United States and the United Kingdom.

Authors:  Ruth R Faden; Kalipso Chalkidou; John Appleby; Hugh R Waters; Jonathon P Leider
Journal:  Milbank Q       Date:  2009-12       Impact factor: 4.911

3.  Socioeconomic inequalities in cancer survival in England after the NHS cancer plan.

Authors:  B Rachet; L Ellis; C Maringe; T Chu; U Nur; M Quaresma; A Shah; S Walters; L Woods; D Forman; M P Coleman
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

4.  A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Gemma L Crighton; Erica M Wood; Simon Stanworth; Marialena Trivella; Carolyn Doree; Alan Tinmouth; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2014

5.  Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey.

Authors:  Georgios Lyratzopoulos; Josephine M Barbiere; David C Greenberg; Karen A Wright; David E Neal
Journal:  BMJ       Date:  2010-04-21

6.  Determining the date of diagnosis--is it a simple matter? The impact of different approaches to dating diagnosis on estimates of delayed care for ovarian cancer in UK primary care.

Authors:  A Rosemary Tate; Alexander G R Martin; Tarita Murray-Thomas; Sarah R Anderson; Jackie A Cassell
Journal:  BMC Med Res Methodol       Date:  2009-06-23       Impact factor: 4.615

7.  Delay in diagnostic workup and treatment of esophageal cancer.

Authors:  Brechtje A Grotenhuis; Pieter van Hagen; Bas P L Wijnhoven; Manon C W Spaander; Hugo W Tilanus; Jan J B van Lanschot
Journal:  J Gastrointest Surg       Date:  2009-12-10       Impact factor: 3.452

8.  Trends and variation in the management of oesophagogastric cancer patients: a population-based survey.

Authors:  Georgios Lyratzopoulos; Josephine M Barbiere; Chetna Gajperia; Michael Rhodes; David C Greenberg; Karen A Wright
Journal:  BMC Health Serv Res       Date:  2009-12-15       Impact factor: 2.655

9.  Social variations in access to hospital care for patients with colorectal, breast, and lung cancer between 1999 and 2006: retrospective analysis of hospital episode statistics.

Authors:  Rosalind Raine; Wun Wong; Shaun Scholes; Charlotte Ashton; Austin Obichere; Gareth Ambler
Journal:  BMJ       Date:  2010-01-14

10.  Cancer survival in England and the influence of early diagnosis: what can we learn from recent EUROCARE results?

Authors:  C S Thomson; D Forman
Journal:  Br J Cancer       Date:  2009-12-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.